Again, PRN blood pressure medications for asymptomatic hypertension in hospitalized patients causes harm: pubmed.ncbi.nlm.nih.gov/39585709/

New publication co-led with Griffin Bullock! 📊 Wide variability in IV diuretic dosing for acute HF, even within a single institution. ⏱️ Delays in 1st, 2nd, & max doses = longer hospital stays. #CardioSky #PharmSKy www.sciencedirect.com/science/arti...

You can now watch this #JACC Journal Club's #AHA24 webinar discussing #SUMMIT CMR Substudy on Youtube www.youtube.com/watch?v=61rd... #CardioSky #MedSky @chriskramermd.bsky.social @natstokes.bsky.social @jaccjournals.bsky.social @accintouch.bsky.social

Can AI automate HF adjudication in global clinical trials? Our latest #AHA2024 SimPub @CircHF In the DELIVER trial, our AI model for HF hosp was -Accurate -Generated identical treatment estimate for dapa as human CEC -Extracts evidence of HF Paper: twtr.to/7qxb_

My comments on the KRAKEN trial of #muvalaplin to Medscape. #lipids #LPa #CardioSky #AHA24

#AHA24 #CardioSky #MedSky

What do we need to focus on de-prescribing on CVD? Dr. Schwartz gives a good state of the field. Polypharmacy 💊💊 + age = higher complications & 💊🚫 interactions. Huge need to systematically withdrawal low-value “inappropriate” medications #AHA24 #CardioSky

Congratulations to these new FAHAs! 👏 🎉 🙌 Help us welcome them to the fam#AHA24#AHA24

#AHA24 #CardioSky #MedSky AHA @americanheart.bsky.social ACC @accintouch.bsky.social AHA Sciences @ahascience.bsky.social AHA Journals @ahajournals.bsky.social JAMA @jamacurrent.bsky.social ASPC @aspcardio.bsky.social Am J Prev Card @ajpcardio.bsky.social J Card Fail @jcardfail.bsky.social

Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical Trials www.ahajournals.org/doi/10.1161/... #Circulation #AHA24 #CardioSky #MesSky @ahajournals.bsky.social @ahascience.bsky.social

CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy www.nejm.org/doi/full/10.... #NEJM #AHA24 #CardioSky #MedSky @ahascience.bsky.social @dramitkhera.bsky.social

#AHA24 #CardioSky @ahascience.bsky.social

Lyndsey DeGroot from CU presenting findings from the ADAPT RCT! #AHA24 jamanetwork.com/journals/jam...

Amazing @erinmichos.bsky.social teaching us about new drugs & technologies in lipid management Love seeing 🦋 on her slides. #AHA24 #CardioSky #MedSky #WIC @ahascience.bsky.social @aspcardio.bsky.social @dramitkhera.bsky.social @drmarthagulati.bsky.social @minnowwalsh.bsky.social

#AHA24 #CardioSky #MedSky #WIC #CardioObstetrics Go Red For Women and Underrepresented Populations Join us now in Main Event II @garimasharmamd.bsky.social @ahascience.bsky.social @minnowwalsh.bsky.social @drmarthagulati.bsky.social @dramitkhera.bsky.social

Happening now in Main II. All about Heart Disease in women. #AHA24 #cardiosky

Dr Minc on strategies to tackle geographical disparities in #PAD “amputation hot spots” in WV using implementation science, provider ed on foot exam and #PAD, “hot foot hotline” #AHA24 #Cardiosky

@TheLancet session at #AHA24 starting now! #obesity 🫀Malnutrition was a problem but now obesity is taking over worldwide with few exceptions 🫀Severe obesity has also ⤴️ 🫀BMI doesn’t reflect obesity as well as waist-to-height ratio 🫀⤴️ diabetes follows obesity

Happening now in N226! Come explore the intersection between obesity and heart failure. What type of fat is it? 🤗🤔😀 #AHA24 #HEATAF #adipocyteheterogeneity #hotfat #standingroomonly @ahascience.bsky.social

#AHA24 version of #Skytorial for #CardioSky newcomers 1/2 🦋 Unlike Twitter, liking a post does NOT promote or increase visibility of that post. You need to REPOST. 🦋 Follow #CardioSky community by using this starter pack go.bsky.app/562nfhZ #MedSky @ahascience.bsky.social

Can health tech 💻like NLP and LLMs help with pragmatic use of clinical trials? Let’s find out! #AHA24 #CardioSky

Important work by Dr. Jennifer Campbell & moderated by @PowellWileyLab on association btw redlining 🏠🛑 and prevalent T2DM 🍫. Potential direct association 📈(estimate 0.28; P<0.001) With indirect pathways through healthcare access 🏥, education 📚, & social risk ⚠️ #AHA24 #CardioSky

Excited to see all the coverage on #AHA24! Helps reduce the fomo 😂 keep the posts coming #CardioSky

Amazing results from BPROAD trial showing lowering BP in T2DM to SBP<120 vs <140 mmHg reduces 4 points MACE HR0.79(.69-.9). Will be interesting to see how many are on SGLT2i or GLP1ra #AHA24

Intensive Blood-Pressure Control in Patients with Type 2 Diabetes www.nejm.org/doi/full/10....

#LBCT #SUMMIT trial #AHA24 💥 Treatment with tirzepatide led to ⤵️risk of a composite of death from cardiovascular 🫀 causes or worsening heart failure 🆚 placebo and improved health status in patients with HFpEF+obesity 📎 @NEJM www.nejm.org/doi/full/10....

SUMMIT: Among 731 individuals with HFpEF & BMI>30, tirzepatide v placebo led to 38% reduction in CV death / HF events & improvement in symptoms. Interestingly, at least consistent benefit for NTproBNP<200 www.nejm.org/doi/full/10.... @ahascience.bsky.social #AHA24

SUMMIT @ #AHA24 N=731 w/ obesity + HFpEF (EF >=50%) + enrichment factors randomized to tirzepatide vs placebo, >50% 🙋‍♀️!, most w/ low BNP, med f/u 104 wks Co-PEP: (1) worsening HF or CV 💀 (2) KCCQ Tirzepatide ➡️ HR 0.62 for worsening HF/CV 💀, driven by worsening HF www.nejm.org/doi/full/10....

Thank you @accintouch.bsky.social & @chriskramermd.bsky.social @minnowwalsh.bsky.social for your support #AHA24 #CardioSky #MedSky

Session on best way to achieve BP control

New therapeutic option in the works for ATTR amyloid? Nexiguran ziclumeran (nex-z), a CRISPR/Cas9 therapy that 🛑TTR synthesis, showing promise with rapid ⬇️ in TTR by 89%, with possible stability or improvement in dz progression #AHA24

SUMMIT trial presenting now - Tirzepatide in HFpEF (>50 LVEF) w/ BMI>=30 + 1 of following: LA enlargement, ⬆️ LV filling pressure, or ⬆️ BNP. #AHA24 #CardioSky

My colleagues and I will be sharing all the happenings from #AHA24 so that all those here in person know what sessions to check out and for those at home, to inspire you to come along next time!

Presenting now! BPROAD study - intensive BP control vs standard (SBP< 120 vs 140) in HTN+T2DM+age >=50+⬆️❤️risk. #AHA24 #LBCTs #CardioSky

Starting us off is Dr. Keith B. Churchwell, the president of the AHA #AHA24 @ahascience.bsky.social

Starting off strong with presentations from Drs Susmita Parashar, Yvonne Commodore-Mensah and Khadijah Breathett #AHA24 @ahascience.bsky.social

Great talk by Dr. Breathett on implementation science in HF! Big issues within heart transplant referral/use by race, sex, and SDoH, but encouraging research and frameworks to improve #AHA24 #QCOR24 #CardioSky

Exciting times ahead at #AHA24! Join us as we kick off with groundbreaking sessions on cardiovascular health, science, and innovation at in Chicago. Here’s a sneak peek of some can’t-miss highlights! 🧵👇

Dr. LaPrincess Brewer discusses important factors in equity and context for CBPR #AHA24 #QCOR24 #CardioSky

What is the right methodology to test AI-enabled diagnostic tools? Dr. Faraz Ahmad talks about hybrid models between RCTs and implementation science. #AHA24 #QCOR24 #CardioSky

How do we elevate registry collection? Dr. Tom Maddox shares that the answer may be through NLP and LLMs, with some QC oversight! #AHA24 #QCOR24 #CardioSky

Off the Chicago for what should be a wonderful #AHA24 and #QCOR24. Hope to see everyone there and connect! #CardioSky